A subgroup meta-analysis was conducted based on the type of GLP-1 RA used, separately for three treatment durations: 3 months, 6 months, and 12 months
Disrupted sleep affects cortisol
The most commonly reported side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain - typically dose-dependent and most prominent during dose escalation
Drugmakers have lowered out-of-pocket costs in recent months, but many patients still pay about $350 a month
The dataset connects claims, labs and EHR, including physician notes to analyse: Who meets drug label or payer criteria based on actual BMI and comorbidities How titration and dosing progress in real-world care What metabolic outcomes patients achieve over time Which safety signals, such as liver or renal changes, emerge across populations Why patients discontinue or switch treatments, as documented in notes See real-world GLP-1 evidence in action Register for our webinar where we dive deeper into GLP-1 real-world evidence
Patients interested in currently available therapies can learn more about semaglutide and tirzepatide as part of a medically supervised approach
